A company leader advises that the growing need for high-potency active pharmaceutical ingredients calls for CDMOs that consistently deliver quality at scale.
This month’s news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.
The expansion collates WuXi AppTec’s technology platform small molecule capabilities, including screening, discovery biology, pharmacology, and process R&D.
The CRO WuXi AppTec and Schrödinger have launched Faxian Therapeutics, a new company that will focus on accelerating drug discovery and advancing new therapies through global collaboration.
The multi-phase collaboration between WuXi AppTec Research Service Division and Cyclica looks to advance polypharmacology in drug discovery using AI-augmented technology.
China is determined to become a bigger player in the pharmaceutical market, and with more opportunities for cross-border collaboration, WuXi AppTec aims to be the world’s largest platform for drug research and development.
WuXi AppTec’s acquisition of ResearchPoint Global (RPG) follows the release of a new guideline that will enable Chinese companies to accept clinical trial data from other countries.
WuXi AppTec’s LabNetwork is collaborating with Reaxys in order to simplify customer’s purchasing decisions and expand exposure to the WuXi eCommerce platform.
